Your browser doesn't support javascript.
loading
Research progress on neoadjuvant immunotherapy for esophageal cancer / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology ; (6): 638-643, 2023.
Article in Chinese | WPRIM | ID: wpr-993243
ABSTRACT
Neoadjuvant therapy, especially neoadjuvant chemoradiotherapy, has become the standard preoperative treatment for locally advanced resectable esophageal cancer, whereas the recurrence and distant metastasis rates after surgery remain high. In recent years, programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors have been widely adopted in immunotherapy for cancer. Whether PD-1/PD-L1 immune checkpoint inhibitors combined with neoadjuvant chemotherapy / neoadjuvant chemoradiotherapy could further improve clinical efficacy, increase the complete surgical resection rate and safety are current research hotspots. In this article, neoadjuvant immunotherapy combined with chemotherapy / radiochemotherapy for esophageal cancer was reviewed.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Radiation Oncology Year: 2023 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Radiation Oncology Year: 2023 Type: Article